Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check
Gilead Sciences has extended its tender offer to acquire Arcellx until April 24, 2026, after only 7.5% of Arcellx shares were tendered by the initial deadline. This delay highlights increasing caution among investors and stricter regulatory scrutiny in the biotech M&A market, despite the deal's strategic importance to Gilead's oncology expansion. The situation serves as a case study for the 2026 biotech M&A landscape, where contingent value rights are frequently used to mitigate risk.
Key facts: Gilead Extends Arcellx Deal; $115+CVR; HIV Coverage Varies
Gilead has extended its tender offer for Arcellx until April 24, 2026, for $115 cash per share plus a contingent value right of up to $5 if anito-cel reaches $6 billion in sales by 2029. Approximately 4.39 million shares have been tendered in the deal, valued at around $7.8 billion, with closing expected in Q2 2026. Separately, Gilead Sciences' long-acting HIV prevention injection faces variable insurer coverage and patient out-of-pocket costs, as it is not yet explicitly covered by the 2023 U.S. task force guidance.
Gilead Sciences, Arcellx see HSR waiting period expire March 31
Gilead Sciences and Arcellx have cleared the Hart-Scott-Rodino premerger waiting period as of March 31. This information was disclosed by Arcellx in a recent US Securities and Exchange Commission filing. The article highlights this as a key regulatory development.
Gilead Extends Tender Offer To Acquire Arcellx
Gilead Sciences has announced an extension of its tender offer to acquire Arcellx. The brief report indicates this is a continuation of the acquisition process between the two companies, Gilead (GILD) and Arcellx (ACLX).
Arcellx (ACLX) 14D-9 amendment: Offer extended to Apr 24; HSR waiting period ended
Arcellx has amended its Schedule 14D-9, announcing an extension of the tender offer by Ravens Sub, Inc./Gilead Sciences until April 24, 2026. The HSR waiting period expired on March 31, 2026, satisfying a key condition for the acquisition. Additionally, the filing discloses new shareholder lawsuits and demand letters alleging disclosure deficiencies, which the company believes are without merit.
Arcellx Inc stock hits all-time high at 114.92 USD
Arcellx Inc.'s stock reached an all-time high of $114.92 USD, reflecting a strong 89% total return over the past year and contributing to a $6.74 billion market capitalization. Despite this milestone, InvestingPro analysis suggests the stock is currently overvalued. This surge comes amidst recent analyst downgrades following Gilead Sciences' announced acquisition of Arcellx for $115 per share plus a contingent value right.
Gilead to buy US biotech Arcellx for up to $7.8 billion
The provided content is extremely bare and does not contain the actual article about Gilead's potential acquisition of Arcellx. Therefore, a meaningful summary cannot be generated. The headline suggests a significant biotech acquisition.
Piper Sandler Downgrades Arcellx(ACLX.US) to Hold Rating, Maintains Target Price $115
Piper Sandler has downgraded Arcellx (ACLX.US) to a Hold rating from an Overweight rating, while keeping its price target at $115. This adjustment follows the company's Q4 2025 earnings report. The analyst firm notes that until the company's lead product, anitocabtagene autoleucel (anito-cel), is fully launched and commercially de-risked, its stock is unlikely to outperform.
Assessing Arcellx (ACLX) Valuation After Strong Returns And Fresh Cancer Immunotherapy Data
Arcellx (ACLX) has seen strong share price growth over the past year, driven by positive data from its cancer immunotherapy pipeline. While its Price-to-Book ratio of 16.7x appears reasonable compared to peers, it is significantly higher than the broader US biotech industry average. However, a Discounted Cash Flow model suggests the stock is trading at a substantial discount to its estimated fair value, despite risks associated with net losses and uncertain clinical trial outcomes.
Assessing Arcellx (ACLX) Valuation After Strong Returns And Fresh Cancer Immunotherapy Data
Arcellx (ACLX) has garnered attention due to strong recent share price performance and positive new data for its cancer immunotherapies. While its Price-to-Book ratio of 16.7x suggests it's expensive compared to the broader US biotech industry, it appears restrained against its closest peers. A Discounted Cash Flow (DCF) model, however, indicates the company might be significantly undervalued, trading at a 76.7% discount with a fair value of $491.75.
Arcellx, Inc. (NASDAQ:ACLX) Given Average Recommendation of "Hold" by Brokerages
Arcellx, Inc. (NASDAQ:ACLX) has received a consensus "Hold" rating from nineteen research firms, with an average one-year target price of $111.87. Despite opening near its 52-week high, the company remains unprofitable, reporting an EPS of -$1.01 against expectations and revenues of $1.65 million, significantly below the anticipated $13.4 million. Insider sales and institutional holdings indicate significant market activity in ACLX stock.
Gilead’s Arcellx Deal Deepens Oncology Focus And Reshapes Investor Risk Profile
Gilead Sciences is acquiring Arcellx in a $7.8 billion deal, gaining full rights to anito cel, a CAR T cell therapy for multiple myeloma. This acquisition expands Gilead's oncology focus beyond antivirals and existing cell therapies, introducing a late-stage asset into a high-need area. Investors should monitor clinical data, regulatory milestones, and integration efforts, considering the deal's impact on Gilead's risk profile, pipeline, and debt levels.
Price-Driven Insight from (ACLX) for Rule-Based Strategy
Arcellx Inc. (NASDAQ: ACLX) shows neutral near and mid-term readings but a positive long-term bias according to AI analysis from Stock Traders Daily. Despite the long-term positive outlook, there is elevated downside risk due to a lack of additional long-term support signals. The analysis provides specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, with detailed entry, target, and stop-loss zones.
Arcellx (ACLX) 10K Form and Latest SEC Filings 2026
This article provides an overview of Arcellx's (ACLX) SEC filings, highlighting that the company has submitted over 264 documents since 2019, with the most recent being a Form SCHEDULE 13G/A on March 26, 2026. It explains the importance of various SEC filing types like 10-K, 10-Q, 8-K, and Form 4 for investors to assess the company's financial health and insider activity. The article also details the historical filing activity for Arcellx, including changes in beneficial ownership and sales of securities by insiders.
ARCELLX PB Ratio: 16.50 — 103% Above Median
Arcellx Inc (ACLX) currently has a Price-to-Book (PB) Ratio of 16.50 as of March 27, 2026, which is 103% above its 10-year median of 8.13 and significantly higher than the Biotechnology industry median of 2.87. GuruFocus rates ACLX with a GF Score of 47/100 and a GF Value of $35.53, indicating it is significantly overvalued compared to its current price of $114.62, and notes 5 warning signs for investors. The article provides a detailed historical analysis of ACLX's PB Ratio, its calculation, comparison to competitors, and explanations of what the ratio signifies.
Vanguard Realignment: Arcellx (ACLX) Beneficial Ownership Reported as 0%
The Vanguard Group filed an amended SCHEDULE 13G/A, reporting 0% beneficial ownership of Arcellx (ACLX) common stock. This change is due to an internal realignment on January 12, 2026, which allows certain Vanguard subsidiaries to report their holdings separately, as per SEC Release No. 34-39538. The filing clarifies that this is an administrative reporting change and not an indication of a sale of shares by Vanguard.
Gilead Sciences stock surges on double blockbuster acquisitions: Arcellx and Ouro Medicines deals re
Gilead Sciences has announced two major acquisitions within a month, purchasing Arcellx and Ouro Medicines, to bolster its biotechnology pipeline. These strategic moves aim to diversify Gilead's portfolio into inflammation diseases and advanced oncology treatments, reducing reliance on its mature HIV franchise. The acquisitions have been met positively by investors, with Gilead's stock showing an uptick, despite potential integration risks and competitive pressures.
Gilead Reportedly Eyes Yet Another Acquisition Worth $2B After Arcellx Deal
Gilead Sciences is reportedly planning to acquire privately-held biotech Ouro Medicine for up to $2 billion to expand its autoimmune disease portfolio. This potential acquisition would follow its recent $7.8 billion deal for Arcellx to gain access to a new multiple myeloma cell therapy. Gilead aims to strengthen its pipeline through targeted acquisitions and partnerships, maintaining a disciplined approach despite significant investments.
Arcellx (NASDAQ:ACLX) Upgraded by Truist Financial to Strong-Buy Rating
Truist Financial has upgraded Arcellx (NASDAQ:ACLX) to a "strong-buy" rating, despite several other firms recently downgrading the stock. The company's consensus rating on MarketBeat remains "Hold" with an average target price of $111.87. Insider selling has been noted, with significant share sales by Rami Elghandour and Christopher Heery, totaling over $11.5 million in sales from insiders within the last 90 days.
Arcellx Inc stock hits all-time high at 114.82 USD
Arcellx Inc. (ACLX) reached an all-time high of $114.82, with its stock currently trading at $114.70 and a market capitalization of $6.71 billion, reflecting a significant 1-year change of 65.04% and 75.35% year-to-date. This surge comes amid Gilead Sciences' announcement to acquire Arcellx for approximately $7.8 billion, leading several financial firms like TD Cowen, Guggenheim, UBS, Stifel, and Evercore ISI to downgrade Arcellx to "Hold" or "Neutral" ratings with price targets around the acquisition offer of $115 per share.
Assessing Arcellx (ACLX) Valuation After A Sharp Share Price Run And Contrasting DCF Signal
Arcellx (ACLX) has seen a significant share price increase, with a 62.86% gain in 30 days, placing its stock at US$114.33. The company's Price-to-Book ratio of 16.7x suggests it's priced for strong expectations compared to the broader biotech sector, though it appears cheaper against a peer group. However, a Discounted Cash Flow (DCF) model indicates a potential 76.5% undervaluation, prompting investors to consider whether the market price fully reflects its long-term potential or if the DCF model's assumptions are overly optimistic.
Arcellx (ACLX) CFO gifts 5,000 shares to family foundation
Arcellx, Inc.'s Chief Financial Officer, Michelle Gilson, gifted 5,000 shares of common stock to a family charitable foundation on March 17, 2026. This transaction was a bona fide gift for no consideration. Despite the transfer, Ms. Gilson retains voting and investment power over the shares through her role as President of the foundation, maintaining her overall economic exposure.
Gilead Pursues Arcellx Deal As Valuation Gap And Debt Draw Focus
Gilead Sciences has agreed to acquire blood cancer drug developer Arcellx for $7.8 billion, aiming to expand its cell-based therapies pipeline and strengthen its oncology presence. The deal includes upfront cash and milestone payments tied to future sales. Despite the strategic acquisition, Simply Wall St highlights a valuation gap for Gilead, noting its shares are trading below analyst targets and an estimated fair value, while also flagging the company's high debt level as a risk.
Gilead Pursues Arcellx Deal As Valuation Gap And Debt Draw Focus
Gilead Sciences is set to acquire Arcellx for $7.8 billion to expand its cell-based therapies in oncology. The deal, structured with upfront and milestone payments, positions Gilead to grow beyond its current portfolio, though the company's valuation gap and high debt levels are key considerations for investors.
Top 2 Health Care Stocks That May Fall Off A Cliff This Month
This article identifies two healthcare stocks, Arcellx Inc (ACLX) and Atea Pharmaceuticals Inc (AVIR), that may be considered overbought based on their high Relative Strength Index (RSI) values. Arcellx has seen a significant gain due to an acquisition announcement by Gilead Sciences, while Atea Pharmaceuticals reacted to an analyst's price target increase. Investors are cautioned to consider momentum indicators when evaluating these stocks.
Is It Too Late To Consider Arcellx (ACLX) After Its Recent Share Price Surge?
Arcellx (ACLX) has seen significant share price appreciation, with a 63.9% return over the past year. Despite this surge, a Discounted Cash Flow (DCF) analysis suggests the company is currently 76.5% undervalued, projecting a fair value of $487.83 per share against a market price of $114.52. While its Price-to-Book ratio is high compared to the industry average, the article indicates that the share price surge may not fully reflect its future potential based on analysts' free cash flow estimates.
Bamco Inc. NY Increases Stake in Arcellx, Inc.
Bamco Inc. NY has increased its stake in Arcellx, Inc. by 6.2% during the third quarter, signaling confidence in the biotech company's pipeline. The institutional investor now owns 550,236 shares of Arcellx, valued at approximately $45.17 million, representing about 0.95% of the company's outstanding shares. Arcellx is a clinical-stage biopharmaceutical company focused on developing cell therapies for oncology and autoimmune diseases.
Bamco Inc. NY Has $45.17 Million Stake in Arcellx, Inc. $ACLX
Bamco Inc. NY increased its stake in Arcellx, Inc. (NASDAQ:ACLX) by 6.2% in the third quarter, bringing its total holdings to 550,236 shares valued at $45.17 million. Other institutional investors also adjusted their positions, with Decheng Capital LLC, American Century Companies Inc., and Vestal Point Capital LP significantly increasing their holdings. Analysts currently have an average "Hold" rating on Arcellx, with a consensus target price of $111.87.
Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Arcellx, Inc. to Gilead Sciences, Inc. KSF is scrutinizing the adequacy of the $115.00 cash per share plus a $5.00 contingent value right, and the process leading to this offer, believing it might undervalue the company. Shareholders are encouraged to contact KSF if they believe the transaction undervalues Arcellx or wish to discuss their legal rights.
Gilead Sciences to buy Arcellx in deal valued at $7.8 billion
NULL
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Declines By 38.0%
Short interest in Arcellx, Inc. (NASDAQ:ACLX) saw a significant decline of 38.0% in February, totaling 5,763,954 shares and representing approximately 10.8% of the company's stock. Insider selling has also been noted, with several transactions totaling over $11 million in the last 90 days. Despite a consensus "Hold" rating from analysts and a target price of $111.87, the stock is trading near its 52-week high with a market cap of $6.68 billion.
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Arcellx, Inc. to Gilead Sciences, Inc. for $115.00 cash per share plus a $5.00 contingent value right. KSF is evaluating whether the proposed consideration and the process leading to the sale adequately value Arcellx, Inc. and is encouraging shareholders who believe the transaction undervalues the company to contact them.
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise?
Gilead Sciences (GILD) is acquiring Arcellx (ACLX) for $7.8 billion to strengthen its cell therapy franchise, which has seen declining sales due to competition. The acquisition will give Gilead full control over Arcellx's lead candidate, anito-cel (anitocabtagene autoleucel), a potential fourth-line treatment for multiple myeloma that is currently awaiting FDA approval. This strategic move aims to streamline development, enhance long-term margins, and diversify Gilead's revenue beyond its dominant HIV business into oncology.
Gilead’s US$7.8b Arcellx Deal Deepens Cell Therapy Diversification
Gilead Sciences plans to acquire Arcellx for up to $7.8 billion to expand its cancer cell therapy pipeline, specifically targeting multiple myeloma. This acquisition, expected to close in Q2 2026, aims to diversify Gilead's portfolio beyond antiviral therapies and strengthen its oncology presence. However, it also introduces risks related to capital allocation, integration, and the complexities of cell therapy development and commercialization.
Gilead’s US$7.8b Arcellx Deal Deepens Cell Therapy Diversification
Gilead Sciences is acquiring Arcellx for up to $7.8 billion to expand its cancer cell therapy pipeline, particularly in multiple myeloma. This strategic move aims to diversify Gilead's revenue streams beyond its established antiviral business, integrating Arcellx's CAR T cell candidate developed with Kite Pharma. Investors will watch for regulatory approvals, integration plans, and clinical progress as the deal is expected to close in Q2 2026.
Victory Capital Management Inc. Has $14.13 Million Stock Position in Arcellx, Inc. $ACLX
Victory Capital Management Inc. reduced its stake in Arcellx, Inc. (NASDAQ:ACLX) by 13.9% in the third quarter, now owning 172,049 shares valued at $14.13 million. Several other institutional investors also adjusted their positions in the company, which now has 96.03% institutional ownership. Wall Street analysts have issued mixed ratings for Arcellx, with a consensus "Hold" rating and an average target price of $111.87.
Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion
Gilead Sciences announced its acquisition of Arcellx, Inc. for up to $7.8 billion, paying $115 per share, a 79% premium. This move aims to expand Gilead's cancer treatment pipeline, particularly bolstering its cell therapy position with anito-cel, an investigational CAR-T treatment for multiple myeloma. The deal, expected to close in Q2 2026, is Gilead's largest since 2020 and signifies its strategic shift beyond HIV and liver disease therapies.
American Century Companies Inc. Has $33.82 Million Position in Arcellx, Inc. $ACLX
American Century Companies Inc. has reduced its stake in Arcellx, Inc. (NASDAQ:ACLX) by 4.5% in the third quarter, now holding 411,930 shares valued at approximately $33.82 million. This move comes as analysts have largely adopted a cautious "Hold" rating for Arcellx, with a consensus price target of $111.87, following recent downgrades. The company's latest quarterly earnings reported an EPS of -$1.01 (in line with estimates) but a significant revenue miss, alongside notable insider stock sales totaling $11.5 million in the past 90 days.
Blue Owl Capital Holdings LP Buys Shares of 26,823 Arcellx, Inc. $ACLX
Blue Owl Capital Holdings LP recently acquired a new stake of 26,823 shares in Arcellx, Inc. (NASDAQ: ACLX) during the third quarter, valued at approximately $2.20 million. Other institutional investors like Teacher Retirement System of Texas and CWM LLC also modified their holdings, while insiders sold a significant number of shares totaling over $11.5 million in the last three months. Analyst ratings for Arcellx are predominantly "Hold," with an average price target of $111.87, and the company reported earnings per share inline with expectations but missed revenue forecasts for its last quarter.
Arcellx, Inc. (NASDAQ:ACLX) Receives Average Rating of "Hold" from Analysts
Arcellx, Inc. (NASDAQ:ACLX) has received an average "Hold" rating from nineteen analysts, with a consensus 12-month price target of $111.87. Several analysts recently downgraded their ratings or trimmed price targets following insider selling and the company missing revenue estimates in its latest financial report. Insiders sold over 109,000 shares in the last three months, though institutional investors hold a significant 96.03% stake.
Arcellx Inc stock hits all-time high at 114.27 USD By Investing.com
Arcellx Inc (ACLX) stock has reached an all-time high of $114.27, reflecting an 82% surge over the past year and 75% year-to-date, boosting its market cap to $6.67 billion. This comes despite InvestingPro data suggesting the stock is overvalued and in overbought territory. The company is also in the process of being acquired by Gilead Sciences for $7.8 billion, leading several analyst firms to downgrade Arcellx to "Hold" or "Neutral" with price targets around the acquisition offer of $115 per share.
Top 2 Health Care Stocks That May Crash This Quarter - Arcellx (NASDAQ:ACLX), Anika Therapeutics (NASDAQ:ANIK)
This article identifies two healthcare stocks, Anika Therapeutics (NASDAQ: ANIK) and Arcellx (NASDAQ: ACLX), as potentially overbought based on their Relative Strength Index (RSI) values, signaling a possible pullback in the short term. Anika Therapeutics recently reported strong fourth-quarter results, leading to a significant stock gain, while Arcellx is set to be acquired by Gilead Sciences, which has also driven its stock up. Investors are cautioned to consider this momentum indicator in their trading decisions for these stocks.
ACLX Financials: Income Statement, Balance Sheet & Cash Flow
The article provides a detailed financial overview of ARCELLX INC (ACLX) for fiscal year 2025, including income statement, balance sheet, and cash flow data, alongside key financial ratios and health signals. It highlights the company's weak profitability, revenue decline, and low earnings quality, despite strong liquidity and low leverage. ARCELLX INC scored 39 out of 100 on its Financial Profile, indicating weak overall financial health, with a low Piotroski F-Score of 1 out of 9 and an estimated cash runway of only 5 months.
Arcellx, Inc. (ACLX) Stock Analysis: Navigating Biotech’s Cutting Edge with Strategic Alliances
Arcellx, Inc. (ACLX) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer, with a market capitalization of $6.59 billion. Despite its innovative pipeline and strategic alliance with Kite Pharma, the company faces characteristic biotech volatility with negative revenue growth and no current profits, indicating a high-investment phase. Investors are advised to monitor clinical trial outcomes and regulatory milestones due to the inherent risks and long-term investment perspective required.
Citigroup Inc. Sells 13,427 Shares of Arcellx, Inc. $ACLX
Citigroup Inc. has reduced its stake in Arcellx, Inc. (NASDAQ:ACLX) by 12.6%, selling 13,427 shares and retaining 92,845 shares valued at approximately $7.62 million. This move comes amidst significant insider selling, a substantial revenue miss in Arcellx's earnings report, and multiple analyst downgrades to a "Hold" rating. Despite these negative sentiments and a consensus target price of $111.87, over 96% of the stock is still owned by hedge funds and institutional investors.
TD Asset Management Inc Buys 129,248 Shares of Arcellx, Inc. $ACLX
TD Asset Management Inc significantly increased its stake in Arcellx, Inc. by purchasing an additional 129,248 shares, bringing its total to 232,708 shares valued at approximately $19.1 million. This increase in institutional ownership comes amidst substantial insider selling and a notable revenue shortfall for Arcellx, leading to analyst downgrades and a "Hold" consensus rating. The article details recent insider transactions and analyst reports, highlighting a mixed sentiment surrounding the company's stock performance.
Gilead adds to cell therapy portfolio with $8bn acquisition of Arcellx
Gilead Sciences is acquiring Arcellx for $7.8 billion, expanding its CAR-T cell therapy partnership. This acquisition builds on their 2022 collaboration for anito-cel, an investigational BCMA-directed CAR T-cell therapy for multiple myeloma, which is currently under BLA submission. The deal also grants Gilead access to Arcellx's CAR technology platform, aiming to strengthen its oncology and inflammation portfolio and advance in vivo cell therapy efforts.
Vanguard Group Inc. Sells 37,798 Shares of Arcellx, Inc. $ACLX
Vanguard Group Inc. recently reduced its stake in Arcellx, Inc. by selling 37,798 shares, bringing its total ownership to 7.04% valued at $320.8 million. This comes amidst significant insider selling, with Director Rami Elghandour selling $10.24 million worth of shares. Analyst sentiment is mixed, holding a consensus "Hold" rating, while the stock trades near its 1-year high.
Insider Selling: Arcellx (NASDAQ:ACLX) Insider Sells 89,916 Shares of Stock
Arcellx (NASDAQ:ACLX) Director Rami Elghandour sold 89,916 shares of the company's stock for approximately $10.24 million, reducing his stake by 24.57%. This sale occurred while the stock was trading near its 12-month high and followed multiple analyst downgrades and a significant revenue shortfall in the previous quarter. The insider transaction and recent financial performance have contributed to a negative sentiment surrounding the stock.
Arcellx CEO Elghandour sells $10.2 million in ACLX stock
Arcellx CEO Rami Elghandour sold 89,916 shares of ACLX common stock for approximately $10.2 million on February 27, 2026, to cover tax withholding obligations. The sale occurred while the stock was near its 52-week high, following a 75% year-to-date return. This transaction happened amidst Gilead Sciences' recent announcement to acquire Arcellx for an equity value of about $7.8 billion, leading several analyst firms to downgrade Arcellx to Neutral or Hold.
